Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9091106
Abstract: The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti-ErbB3 monoclonal antibodies that are currently being developed… read more here.
Keywords: erbb3 receptor; erbb3; cancer; bcd090 bcd090 ... See more keywords